Bard Financial Services Inc. Has $12.23 Million Stock Position in Pfizer Inc. $PFE

Bard Financial Services Inc. reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 504,605 shares of the biopharmaceutical company’s stock after selling 3,906 shares during the period. Pfizer makes up approximately 1.5% of Bard Financial Services Inc.’s holdings, making the stock its 14th biggest holding. Bard Financial Services Inc.’s holdings in Pfizer were worth $12,232,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Pacer Advisors Inc. grew its stake in shares of Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock worth $508,164,000 after acquiring an additional 17,957,928 shares in the last quarter. Amundi grew its stake in shares of Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after acquiring an additional 15,758,846 shares in the last quarter. Nuveen LLC bought a new position in shares of Pfizer in the first quarter valued at $389,861,000. Starboard Value LP bought a new position in shares of Pfizer in the fourth quarter valued at $407,730,000. Finally, Goldman Sachs Group Inc. grew its stake in shares of Pfizer by 51.9% in the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after buying an additional 9,041,990 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 3.8%

PFE stock opened at $23.91 on Monday. The company has a market cap of $135.94 billion, a PE ratio of 12.72, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. The business has a 50-day simple moving average of $24.79 and a 200 day simple moving average of $24.27. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer’s payout ratio is currently 91.49%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on PFE shares. HSBC cut their price target on Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a report on Monday, May 19th. Morgan Stanley raised their price target on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Jefferies Financial Group lifted their target price on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, May 21st. Citigroup lifted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Berenberg Bank dropped their target price on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a report on Thursday, May 29th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.